-
2022-501006-34-01
5
2023-03-29
Liver cirrhosis
-
2024-515924-35-00
6
2023-01-16
New-Onset Post-Operative Atrial Fibrillation after CABG
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2023-508389-13-00
5
2022-11-08
Combined endpoint of all-cause mortality, kidney failure, and hospital
-
2023-507461-26-00
5
2022-09-22
Newly diagnosed acute myeloid leukemia (AML)
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2023-507557-16-00
5
2022-08-31
chronic myelogenous leukemia (CML) or Philadelphia Chromosome positive
-
2023-503335-18-00
1
2022-07-29
Chronic myeloid leukemia
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-508963-58-00
4
2022-01-31
Symptomatic hypertrophic cardiomyopathy (HCM)
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2023-508532-56-00
5
2021-10-19
Treatment with a Vitamin K Antagonist due to having a mechanical bilea
-
2024-516392-33-00
5
2021-09-17
Patients (18-75 years) with metastatic and/or refractory soft-tissue
s
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-513950-32-00
4
2020-12-15
Intermediate stage hepatocellular carcinoma (HCC)
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-514494-21-00
4
2020-05-13
autoimmune encephalitis
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)